Tau Cardia

Tau Cardia is an investigational pharmaceutical asset currently in the development pipeline of Youdim Pharmaceuticals. As of early 2024, the project is categorized by the developer as being in stealth mode, meaning that specific details regarding its chemical structure, molecular targets, and precise mechanism of action have not been publicly disclosed. Youdim Pharmaceuticals, founded by Professor Moussa Youdim (co-developer of rasagiline), specializes in the development of multi-target drugs for neurodegenerative and cardiovascular conditions. Based on its name and the company's focus, Tau Cardia is intended for the treatment of cardiovascular diseases, such as heart failure, though its specific therapeutic application within that field remains proprietary.